{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:55:23Z","timestamp":1780588523074,"version":"3.54.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Interferon alfa has activity against multiple myeloma (MM). Modakafusp alfa is an immunocytokine comprising 2 attenuated interferon alfa-2b molecules and an anti-CD38 immunoglobulin G4 antibody, targeting delivery of interferon alfa to CD38-expressing (CD38+) immune and myeloma cells. This phase 1\/2 trial enrolled patients with relapsed\/refractory multiple myeloma with \u22653 prior lines of treatment and refractory to, or intolerant of, \u22651 proteasome inhibitor and \u22651 immunomodulatory drug. During dose escalation, modakafusp alfa was administered at 10 doses in 4 schedules across 13 cohorts. The primary end point was safety for dose escalation, and overall response rate (ORR) for dose expansion. We enrolled 106 patients who had received a median of 6.5 lines of prior therapy; 84% of patients had myeloma previously refractory to an anti-CD38 antibody. The most feasible dosing schedule was every 4 weeks (Q4W), at which the maximum tolerated dose was 3\u00a0mg\/kg. Among 30 patients treated at 1.5 mg\/kg Q4W, the ORR was 43.3%, with a median duration of response of 15.1 months (95% confidence interval [CI], 7.1-26.1); median progression-free survival was 5.7 months (95% CI, 1.2-14). Grade \u22653 adverse events (AEs) occurred in 28 (93.3%) patients, the most common were neutropenia (66.7%) and thrombocytopenia (46.7%); infections were reported in 8 (26.7%) patients (including grade 3 in 4 [16.7%]). Modakafusp alfa therapy induced upregulation of the type 1 interferon gene signature score, increased CD38 receptor density in CD38+ cells, and innate and adaptive immune cell activation. Modakafusp alfa resulted in antitumor activity and immune activation in patients with MM. AEs were primarily hematologic. This trial was registered at www.clinicaltrials.gov as #NCT03215030.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026124","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T14:32:44Z","timestamp":1733322764000},"page":"944-955","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-2566","authenticated-orcid":false,"given":"Dan T.","family":"Vogl","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[{"name":"2Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9342-5635","authenticated-orcid":false,"given":"Sarah A.","family":"Holstein","sequence":"additional","affiliation":[{"name":"3Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Benson","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chaudry","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Biran","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, John Theurer Cancer Center, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8776-1533","authenticated-orcid":false,"given":"Kaveri","family":"Suryanarayan","sequence":"additional","affiliation":[{"name":"7Takeda Development Center Americas, Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Li","sequence":"additional","affiliation":[{"name":"7Takeda Development Center Americas, Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyin","family":"Liu","sequence":"additional","affiliation":[{"name":"7Takeda Development Center Americas, Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Collins","sequence":"additional","affiliation":[{"name":"7Takeda Development Center Americas, Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Parot","sequence":"additional","affiliation":[{"name":"7Takeda Development Center Americas, Inc, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5687-6429","authenticated-orcid":false,"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"8Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2025032119424825800_bib1","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.3390\/cancers13205154","article-title":"Relapsed\/refractory multiple myeloma in 2020\/2021 and beyond","volume":"13","author":"Podar","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2025032119424825800_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2025032119424825800_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/138945011794815329","article-title":"Interferon-alpha in the treatment of multiple myeloma","volume":"12","author":"Khoo","year":"2011","journal-title":"Curr Drug Targets"},{"key":"2025032119424825800_bib4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3389\/fonc.2018.00322","article-title":"Plasticity of type I interferon-mediated responses in cancer therapy: from anti-tumor immunity to resistance","volume":"8","author":"Budhwani","year":"2018","journal-title":"Front Oncol"},{"issue":"11","key":"2025032119424825800_bib5","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","article-title":"Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients","volume":"11","author":"Fritz","year":"2000","journal-title":"Ann Oncol"},{"issue":"20","key":"2025032119424825800_bib6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM199005173222005","article-title":"Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy","volume":"322","author":"Mandelli","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025032119424825800_bib7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/annonc\/mdi125","article-title":"Interferon-alpha as maintenance therapy in patients with multiple\u00a0myeloma","volume":"16","author":"Schaar","year":"2005","journal-title":"Ann Oncol"},{"issue":"1","key":"2025032119424825800_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/imr.12349","article-title":"Human IgG4: a structural perspective","volume":"268","author":"Davies","year":"2015","journal-title":"Immunol Rev"},{"issue":"9","key":"2025032119424825800_bib9","doi-asserted-by":"crossref","first-page":"e0162472","DOI":"10.1371\/journal.pone.0162472","article-title":"Targeting\u00a0attenuated interferon-\u03b1 to myeloma cells with a CD38 antibody induces\u00a0potent tumor regression with reduced off-target activity","volume":"11","author":"Pogue","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"2025032119424825800_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11523-021-00827-0","article-title":"Isatuximab: a review of its use in multiple myeloma","volume":"16","author":"Frampton","year":"2021","journal-title":"Target Oncol"},{"issue":"1","key":"2025032119424825800_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"issue":"10","key":"2025032119424825800_bib12","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.clml.2019.09.192","article-title":"TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFN\u03b1) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in\u00a0vivo","volume":"19","author":"Fatholahi","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 16","key":"2025032119424825800_bib13","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1538-7445.AM2020-5546","article-title":"Abstract 5546: A murine reactive version of TAK-573 (anti-CD38 attenuated IFN\u03b1 fusion protein) shows immunomodulatory and antitumor activity, alone and in combination with standard-of-care agents, in IFNa-insensitive, immunocompetent murine multiple myeloma tumor models","volume":"80","author":"Hara","year":"2020","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2025032119424825800_bib14","first-page":"3112","article-title":"Attenuated interferon-\u03b1 targeted to CD38 expressing multiple myeloma tumor cells induces robust and durable anti-tumor responses through direct anti-proliferative activity in addition to indirect recruitment and activation of M1 macrophages","volume":"130","author":"Pogue","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2025032119424825800_bib15","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"2025032119424825800_bib16","first-page":"999","article-title":"Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Vincent Rajkumar","year":"2014","journal-title":"Am J Hematol"},{"issue":"12","key":"2025032119424825800_bib17","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/leu.2015.290","article-title":"Clarification of the definition of complete response in multiple myeloma","volume":"29","author":"Durie","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"2025032119424825800_bib18","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1093\/hmg\/ddv071","article-title":"A\u00a0robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFN\u03b2 drugs in the treatment of multiple sclerosis","volume":"24","author":"Harari","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"8","key":"2025032119424825800_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor\u2013dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2025032119424825800_bib20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective inhibition of nuclear export with oral Selinexor for treatment of relapsed or refractory multiple myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10027","key":"2025032119424825800_bib21","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase\u00a02 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"2025032119424825800_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"2025032119424825800_bib23","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2352-3026(20)30044-2","article-title":"Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"2025032119424825800_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","article-title":"A\u00a0phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab","volume":"11","author":"Mikhael","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025032119424825800_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"2025032119424825800_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-141219","article-title":"TAK-573, an anti-CD38\/attenuated Ifn\u03b1 fusion protein, has clinical activity and modulates the Ifn\u03b1 receptor (IFNAR) pathway\u00a0in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Vogl","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2025032119424825800_bib27","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1089\/107999099313299","article-title":"Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II","volume":"19","author":"Bauvois","year":"1999","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"2025032119424825800_bib28","doi-asserted-by":"crossref","first-page":"597959","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"2025032119424825800_bib29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1189\/jlb.69.4.605","article-title":"CD38 expression and functional activities are up-regulated by IFN-gamma on human monocytes and monocytic cell lines","volume":"69","author":"Musso","year":"2001","journal-title":"J\u00a0Leukoc Biol"},{"issue":"1","key":"2025032119424825800_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back\u00a0to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"10297","key":"2025032119424825800_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen\u00a0receptor T-cell therapy in patients\u00a0with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2025032119424825800_bib32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2025032119424825800_bib33","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/9\/944\/2357274\/blood_bld-2024-026124-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/9\/944\/2357274\/blood_bld-2024-026124-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T20:47:49Z","timestamp":1742590069000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/9\/944\/534313\/Targeted-interferon-therapy-with-modakafusp-alfa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026124","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}